NIH launches clinical trial for hospital patients, antibody research network
The National Institutes of Health has launched a global clinical trial to test a potential COVID-19 treatment that combines remdesivir with a highly concentrated antibody solution. The phase 3 trial will enroll 500 hospitalized adults who have had COVID-19 symptoms for 12 or fewer days and no serious organ dysfunction, and compare their health status after the combination treatment with participants receiving remdesivir and a placebo. The agency also announced a research network to study the immune response to COVID-19 and increase antibody testing capacity.
Related News Articles
Headline
The Department of Health of Human Services Aug. 21 issued a request for information seeking feedback on immunization categories within the Aug. 10 executive…
Headline
For the 2025-2026 school year, exemptions from one or more vaccines among U.S. kindergartners was at 4.2%, increasing from 3.6% for the previous school year,…
Headline
A study published Aug. 5 by Nature found that COVID-19 infection can reactivate dormant, chronic viruses such as Epstein-Barr and cytomegalovirus. The study…
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…